Follow The Filings

VRTX Vertex Pharmaceuticals

Health Care, filed as VERTEX PHARMACEUTICALS INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • $3K
  • 1 exit

In 2026 Q3 Torray Investment Partners sold out of Vertex Pharmaceuticals.

Who owns VRTX

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust <0.01% Hold 5 $3K History
Torray Investment Partners exited 2026 Q3 Last 2026 Q2 1.0% Exit −1.02% 15,215 $7.6M History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VRTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VRTX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $158M sold by 13 insiders under 10b5-1 plans
  1. Ourania Tatsis EVP, Chief Reg. & Quality Off.
    Planned sale
    $787K 1,500 shares at $524.99 3.2% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  2. Duncan McKechnie EVP, Chief Commercial Officer
    Planned sale
    $800K 1,541 shares at $519.00 12% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  3. Joy Liu EVP and Chief Legal Officer
    Planned sale
    $416K 828 shares at $502.71 4.1% of stake
    Traded Jul 1 Filed Jul 6
    ↗
  4. Carmen Bozic EVP and CMO
    Planned sale
    $288K 596 shares at $482.50 3.7% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  5. Carmen Bozic EVP and CMO
    Planned sale
    $471K 1,020 shares at $462.17 6% of stake
    Traded Jun 18 Filed Jun 23
    ↗
  6. Carmen Bozic EVP and CMO
    Planned sale
    $1.8M 4,062 shares at $450.00 19% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  7. Carmen Bozic EVP and CMO
    Planned sale
    $785K 1,745 shares at $450.00 7.7% of stake
    Traded Jun 5 Filed Jun 9
    ↗
  8. Joy Liu EVP and Chief Legal Officer
    Planned sale
    $364K 828 shares at $439.91 4% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  9. Carmen Bozic EVP and CMO
    Planned sale
    $888K 1,974 shares at $450.00 8% of stake
    Traded May 29 Filed Jun 2
    ↗
  10. Mark E. Bunnage EVP, Chief Scientific Officer
    Planned sale
    $15K 33 shares at $453.45 0.5% of stake
    Traded May 15 Filed May 19
    ↗
  11. Carmen Bozic EVP and CMO
    Planned sale
    $614K 1,354 shares at $453.45 5.2% of stake
    Traded May 15 Filed May 19
    ↗
  12. Carmen Bozic EVP and CMO
    Planned sale
    $3.1M 6,988 shares at $450.00 21% of stake
    Traded May 12 Filed May 14
    ↗
  13. Joy Liu EVP and Chief Legal Officer
    Planned sale
    $469K 1,104 shares at $425.02 5.1% of stake
    Traded May 1 Filed May 5
    ↗
  14. Sangeeta N. Bhatia Director
    Planned sale
    $135K 318 shares at $423.73 6.1% of stake
    Traded May 4 Filed May 5
    ↗
  15. Joy Liu EVP and Chief Legal Officer
    Planned sale
    $439K 978 shares at $449.17 4.3% of stake
    Traded Apr 1 Filed Apr 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 42 stock grants, 42 share withholdings for taxes, 8 option exercises, 4 sales back to the company, and 2 gifts.

Congress

7 members of Congress traded VRTX in the last three years: 6 buys and 8 sales. 7 members listed it in 2025 annual reports.

All Congress trades
  1. David J. Taylor R-OH-2 Sell $1K–$15K Aug 26 filed Sep 5
  2. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  3. David J. Taylor R-OH-2 Sell $1K–$15K Jan 29 filed Feb 2
  4. Julia Letlow R-LA-5 Buy $1K–$15K Oct 23, 2024 filed Jan 13
  5. David J. Taylor R-OH-2 Buy $1K–$15K Aug 7, 2025 filed Sep 2, 2025
  6. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Jun 11, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 8 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07 Filing Doc

Source: SEC EDGAR submissions, updated 8 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.87B $11.02B $12B
Gross profit * $8.61B $9.49B $10.35B
Gross margin * 87.2% 86.1% 86.2%
Net income $3.62B -$0.536B $3.95B
Net margin * 36.7% -4.9% 32.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $14.14B $9.6B $11.2B
Total non-current assets * $8.59B $12.94B $14.44B
Total assets $22.73B $22.53B $25.64B
Total current liabilities $3.55B $3.56B $3.86B
Total non-current liabilities * $1.6B $2.56B $3.12B
Total equity $17.58B $16.41B $18.67B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $3.54B -$0.493B $3.63B
Cash from investing -$3.14B -$3.77B -$0.945B
Cash from financing -$0.562B -$1.49B -$2.26B
Net change in cash -$0.14B -$5.8B $0.516B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.